Perspective Therapeutics Inc (NYSEAMERICAN: CATX) stock closed at $14.18 on 9/3/24 after a major decline of -10.3%. NORMAL trading volume accompanied the decline. The stock has been exceptionally strong relative to the market over the last nine months but has declined -9.6% during the last week.
Current PriceTarget Research Rating
CATX’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to be Value Creation neutral.
Perspective Therapeutics has a current Value Trend Rating of C (Neutral). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Perspective Therapeutics has a very low Appreciation Score of 1 but a very high Power Rating of 96, producing the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment